Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

← catalyst calendar

NCT07190430

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
16actual
Sites
1
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-10-03actualWhen the study began enrolling
Primary completion2025-12-15estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-12-15estimatedThe whole study's end, after follow-up
First posted2025-09-24actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-12-09actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Atopic Dermatitis

Interventions

  • Drug: PF-08049820
  • Drug: Midazolam
  • Drug: Dabigatran Etexilate
  • Drug: Portia (EE and LN) or equivalent oral tablet

Primary outcomes

what the primary-completion date above is the date OF
Pharmacokinetics (PK): Area Under the curve (AUC) of Midazolam
measured From pre-dose up to 24 hours post dose in Periods 1 and 4
PK: Plasma Maximum Concentration (Cmax) of Midazolam
measured From pre-dose up to 24 hours post dose in Periods 1 and 4
PK: Area Under the curve (AUC) of dabigatran
measured From pre-dose up to 48 hours post dose in Periods 2 and 5
PK: Cmax of dabigatran
measured From pre-dose up to 48 hours post dose in Periods 2 and 5
PK: AUC of Ethinyl estradiol and levonorgestrel
measured From pre-dose up to 96 hours post dose in Periods 3 and 6
PK: Cmax of Ethinyl estradiol and levonorgestrel
measured From pre-dose up to 96 hours post dose in Periods 3 and 6

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed